BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 6
• 7
• 8
• 9
• 10
• 11
• 13
• 14
• 15
• 16
• 17
• 18
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 28
• 29
• 30
• 31

• 

  When Quitting is Your Best Option: How to Create Your Exit Strategy

  Do you think it’s time to quit your job? If you are certain that you want to quit, do you have an exit strategy? If not then reading this article is a must for you.

  May 22, 2018

   · 

  3 min read

   · 

  Porschia Parker
• 

  Business

  Biotech CEO’s Wild Stunt and Death Shines Light on Community of Biohackers

  The mysterious death of a biotech startup chief executive officer in late April projected the term biohacker into the forefront of the industry lexicon.

  May 22, 2018

   · 

  3 min read

   · 

  Alex Keown
• 

  BioCapital

  Educational Institutions Highlight Biotech Through Partnerships and Programs

  Educational institutions, even at the high school level, are creating specialized biotechnology training programs to satisfy the growth they see within the biotech industry.

  May 22, 2018

   · 

  2 min read

   · 

  Mark Terry
• 

  Deals

  Ahead of the Takeda-Shire Takeover, Takeda Selling Chinese Joint Venture

  With the acquisition of Dublin-based Shire by Japan-based Takeda Pharmaceutical pretty much a done-deal, Takeda appears to be getting its financial house in order before it closes.

  May 22, 2018

   · 

  2 min read

   · 

  Mark Terry
• Lonza Further Strengthens Hepatocytes Portfolio with Addition of Hepatic Non-Parenchymal Cells

  Lonza announced the addition of hepatic stellate cells, Kupffer cells and liver-derived endothelial cells to its extensive hepatocytes portfolio.

  May 22, 2018

   · 

  4 min read
• 

  Biotech Bay

  GRAIL Grabs $300 Million Ahead of Possible IPO on Hong Kong Exchange

  With a new chief executive officer on board, GRAIL, Inc. has secured a whopping $300 million in an oversubscribed Series C financing round led by multiple Chinese investment groups.

  May 22, 2018

   · 

  3 min read

   · 

  Alex Keown
• 

  Business

  Celgene’s Deal Boss Golumbeski Made a Quiet Exit in April

  Celgne’s head of business development, George Golumbeski, has also left the company.

  May 22, 2018

   · 

  3 min read

   · 

  Mark Terry
• 

  Deals

  Who are the Top 3 Biotech Takeover Targets?

  Most investors thought 2018 would be a big year for mergers and acquisitions in the biopharma industry because of changes to the tax law, and so far they’ve been right.

  May 22, 2018

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Allergan Draws on Another Aptinyx Compound to Complement its Phase III Depression Drug

  Allergan has exercised an option to acquire an oral small molecule compound from Illinois-based Aptinyx, a spinout of Naurex, Inc., which the Irish company acquired in 2015. The company will use it as a complement to a Phase III depression treatment.

  May 22, 2018

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Sesen Bio Shares Plunge Despite Reporting Positive Interim Phase III Results

  Shares of newly dubbed Sesen Bio (formerly Eleven Biotherapeutics) have plunged 23 percent after the company released positive, three-month data from its ongoing Phase III high-grade non-muscle invasive bladder cancer (NMIBC) trial.

  May 22, 2018

   · 

  2 min read

   · 

  Alex Keown